Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures

References

1. 1.↵
   1. Qureshi AI,
   2. Luft AR,
   3. Sharma M,
   4. et al

   . Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures. Part II. Clinical aspects and recommendations. Neurosurgery 2000;46:1360–75, discussion 1375–76

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Krpski WC,
   2. Bass A,
   3. Kelly AB,
   4. et al

   . Heparin-resistant thrombus formation by endovascular stents in baboons: interruption by a synthetic antithrombin. Circulation 1990;82:570–77

   Abstract/FREE Full Text
3. 3.↵
   1. Ries T,
   2. Buhk J-H,
   3. Kucinski T,
   4. et al

   . Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816–21

   Abstract/FREE Full Text
4. 4.↵
   1. Riedel C,
   2. Tietke M,
   3. Alfke K,
   4. et al

   . Subacute stent thrombosis in intracranial stenting. Stroke 2009;40:1310–14

   Abstract/FREE Full Text
5. 5.↵
   1. Sutton JM,
   2. Ellis SG,
   3. Roubin GS,
   4. et al

   . Major clinical events after coronary stenting: the multicenter registry of acute and elective Gianturco-Roubin stent placement—the Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994;89:1126–37

   Abstract/FREE Full Text
6. 6.↵
   VerifyNow aspirin assay [package insert]. San Diego, California: Accumetrics.
7. 7.↵
   1. Smith JW,
   2. Steinhubl SR,
   3. Lincoff AM,
   4. et al

   . Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620–25

   Abstract/FREE Full Text
8. 8.↵
   1. Ang L,
   2. Mahmud E

   . Monitoring oral antiplatelet therapy: is it justified? Ther Adv Cardiovasc Dis 2008;2:485–96

   Abstract/FREE Full Text
9. 9.↵
   1. Nielsen HL,
   2. Kristensen SD,
   3. Thygesen SS,
   4. et al

   . Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008;123:267–73

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Antman EM,
    2. Wiviott SD,
    3. Murphy SA,
    4. et al

    . Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028–33

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Malinin A,
    2. Pokov A,
    3. Spergling M,
    4. et al

    . Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277–84

    CrossRefPubMedWeb of Science
12. 12.↵
    VerifyNow P2Y12 Assay [Package Insert]. San Diego, California: Accumetrics.
13. 13.↵
    1. Steinhubl SR,
    2. Talley JD,
    3. Braden GA,
    4. et al

    . Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572–78

    Abstract/FREE Full Text
14. 14.↵
    1. Lakkis NM,
    2. George S,
    3. Thomas E,
    4. et al

    . Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter Cardiovasc Interv 2001;53:346–51

    CrossRefPubMed
15. 15.↵
    1. Carville DG,
    2. Schleckser PA,
    3. Guyer KE,
    4. et al

    . Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998;30:171–77

    PubMed
16. 16.↵
    Helena Laboratories. Plateletworks: Platelet Function Kits. http://www.helena.com/plateletworks.html. Accessed January 2011
17. 17.↵
    1. van Werkum JW,
    2. Kleibeuker M,
    3. Postma S,
    4. et al

    . A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010;140:123–26

    CrossRefPubMed
18. 18.↵
    1. Linnemann B,
    2. Schwonberg J,
    3. Rechner AR,
    4. et al

    . Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010;89:597–605

    CrossRefPubMed
19. 19.↵
    1. Kundu SK,
    2. Heilmann EJ,
    3. Sio R,
    4. et al

    . Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost 1995;21(suppl 2):106–12

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Fressinaud E,
    2. Veyradier A,
    3. Truchaud F,
    4. et al

    . Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325–31

    Abstract/FREE Full Text
21. 21.↵
    1. Homoncik M,
    2. Jilma B,
    3. Hergovich N,
    4. et al

    . Monitoring of aspirin (ASPIRIN) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316–21

    PubMedWeb of Science
22. 22.↵
    1. Koscielny J,
    2. von Tempelhoff GF,
    3. Ziemer S,
    4. et al

    . A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:155–66

    Abstract/FREE Full Text
23. 23.↵
    1. Fattorutto M,
    2. Pradier O,
    3. Schmartz D,
    4. et al

    . Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003;90:692–93

    Abstract/FREE Full Text
24. 24.↵
    1. Marshall PW,
    2. Williams AJ,
    3. Dixon RM,
    4. et al

    . A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997;44:151–55

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Golanski J,
    2. Pluta J,
    3. Baraniak J,
    4. et al

    . Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists–in vitro experience. Clin Chem Lab Med 2004;42:25–29

    CrossRefPubMed
26. 26.↵
    1. Kotzailias N,
    2. Elwischger K,
    3. Sycha T,
    4. et al

    . Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis 2007;16:199–202

    CrossRefPubMed
27. 27.↵
    1. Pidcock M,
    2. Harrison P

    . Can the PFA-100 be modified to detect P2Y12 inhibition? J Thromb Haemost 2006;4:1424–26

    CrossRefPubMed
28. 28.↵
    1. Koessler J,
    2. Kobsar AL,
    3. Rajkovic MS,
    4. et al

    . The new INNOVANCE(R) PFA P2Y cartridge is sensitive to the detection of the P2Y receptor inhibition. Platelets 22:19–25
29. 29.↵
    1. Varon D,
    2. Dardik R,
    3. Shenkman B,
    4. et al

    . A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997;85:283–94

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Varon D,
    2. Lashevski I,
    3. Brenner B,
    4. et al

    . Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:S187–93

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Knobler H,
    2. Savion N,
    3. Shenkman B,
    4. et al

    . Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998;90:181–90

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Kenet G,
    2. Lubetsky A,
    3. Shenkman B,
    4. et al

    . Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998;101:255–59

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Shenkman B,
    2. Inbal A,
    3. Tamarin I,
    4. et al

    . Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. Br J Haematol 2003;120:597–604

    CrossRefPubMed
34. 34.↵
    1. Savion N,
    2. Shenkman B,
    3. Tamarin I,
    4. et al

    . Transient adhesion refractoriness of circulating platelets under shear stress: the role of partial activation and microaggregate formation by suboptimal ADP concentration. Br J Haematol 2001;112:1055–61

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Spectre G,
    2. Brill A,
    3. Gural A,
    4. et al

    . A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 2005;16:293–99

    CrossRefPubMed
36. 36.↵
    1. Li CK,
    2. Hoffmann TJ,
    3. Hsieh PY,
    4. et al

    . The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury. Thromb Res 1998;92:S67–77

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Fricke W,
    2. Kouides P,
    3. Kessler C,
    4. et al

    . A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004;2:763–68

    CrossRefPubMed
38. 38.↵
    1. Simon DI,
    2. Liu CB,
    3. Ganz P,
    4. et al

    . A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 2001;52:425–32

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Harrison P

    . Platelet function analysis. Blood Rev 2005;19:111–23

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Campbell J,
    2. Ridgway H,
    3. Carville D

    . Plateletworks: a novel point of care platelet function screen. Mol Diagn Ther 2008;12:253–58

    PubMed
41. 41.↵
    1. Harle CC

    . Point-of-care platelet function testing. Semin Cardiothorac Vasc Anesth 2007;11:247–51

    Abstract/FREE Full Text
42. 42.↵
    1. Gremmel T,
    2. Steiner S,
    3. Seidinger D,
    4. et al

    . Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009;101:333–39

    PubMed
43. 43.↵
    1. Breet NJ,
    2. van Werkum JW,
    3. Bouman HJ,
    4. et al

    . Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–62

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Braunwald E,
    2. Angiolillo D,
    3. Bates E,
    4. et al

    . Antiplatelet therapy and platelet function testing: introduction. Clin Cardiol 2008;31(3 supple 1):I1

    CrossRefPubMed
45. 45.↵
    1. Mukherjee D,
    2. Chew DP,
    3. Robbins M,
    4. et al

    . Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. J Thromb Thrombolysis 2001;11:151–54

    CrossRefPubMed
46. 46.↵
    1. Jacopo G,
    2. Elisabetta V,
    3. Silverio S,
    4. et al

    . Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007;121:407–12

    CrossRefPubMed
47. 47.↵
    1. Chen WH,
    2. Lee PY,
    3. Ng W,
    4. et al

    . Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122–26

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Buch AN,
    2. Singh S,
    3. Roy P,
    4. et al

    . Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2007;99:1518–22

    CrossRef
49. 49.↵
    1. Gulmez O,
    2. Yildirir A,
    3. Kaynar G,
    4. et al

    . Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. J Thromb Thrombolysis 2008;25:239–46

    CrossRefPubMed
50. 50.↵
    1. Buonamici P,
    2. Marcucci R,
    3. Migliorini A,
    4. et al

    . Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–17

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Pinto Slottow TL,
    2. Bonello L,
    3. Gavini R,
    4. et al

    . Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009;104:525–30

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Price MJ,
    2. Berger PB,
    3. Teirstein PS,
    4. et al

    . Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Price MJ,
    2. Angiolillo DJ,
    3. Teirstein PS,
    4. et al

    . Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention. A time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011:124:1132–7

    Abstract/FREE Full Text
54. 54.↵
    1. Eshtehardi P,
    2. Windecker S,
    3. Cook S,
    4. et al

    . Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159:891–98 e1

    CrossRefPubMed
55. 55.↵
    1. Gori AM,
    2. Marcucci R,
    3. Migliorini A,
    4. et al

    . Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734–39

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Tavassoli N,
    2. Voisin S,
    3. Carrie D,
    4. et al

    . High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs 2010;10:29–35

    CrossRefPubMed
57. 57.↵
    1. Han Y,
    2. Li Y,
    3. Wang S,
    4. et al

    . Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733–39

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Chen KY,
    2. Rha SW,
    3. Li YJ,
    4. et al

    . Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207–14

    Abstract/FREE Full Text
59. 59.↵
    1. Sibbing D,
    2. Schulz S,
    3. Braun S,
    4. et al

    . Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250–56

    CrossRefPubMedWeb of Science
60. 60.↵
    1. Pandya DJ,
    2. Fitzsimmons BF,
    3. Wolfe TJ,
    4. et al

    . Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64–69

    CrossRefPubMedWeb of Science
61. 61.↵
    1. Lee DH,
    2. Arat A,
    3. Morsi H,
    4. et al

    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94

    Abstract/FREE Full Text
62. 62.↵
    1. Qureshi AI,
    2. Siddiqui AM,
    3. Hanel RA,
    4. et al

    . Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry. Neurosurgery 2004;54:307–16, discussion 316–17

    CrossRefPubMed